BARDA drives some of our most advanced scientific research. It funds developments of vaccines, drugs, diagnostics, and other tools to fight emerging diseases and national health threats. Over the past few weeks, BARDA reviewed 22 MRNA vaccine development investments and began canceling them. Let me explain why. Most of these shots are for flu or Covid. But as the pandemic showed us, MRNA vaccines don't perform well against viruses that infect the upper respiratory tract. (00:24–00:34)
CLAIM
Asserts that BARDA has started canceling 22 MRNA vaccine development investments.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
